Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What up with that TWEET?
Enzolytics continues its onward and upward march towards strategic partnerships and a stronger Intellectual Property portfolio.
#ENZC #HIV #COVID19 #AI #Gileads #EliLilly #Patent #Monoclonal #Antibodies #acquisition #partnership #immunome
As much as all here would love to see a license from Gilead, one must realize Gilead makes billions off of HIV products. Their older drugs were toxic to bone and kidneys and their newer ones aren't much better.
Putting aside remdesivir, the Gilead story right now is one focused on change. The company, which shot to pharmaceutical prominence in 2013 with the Food and Drug Administration approval of the hepatitis-C cure Sovaldi, has lately turned its gaze on oncology. (That’s the thing about developing a cure; at its peak, Sovaldi brought in $10 billion in 2014, but demand fell off as fewer people were in need of treatment.)
Since the beginning of March, the drugmaker has signed two cancer-focused deals: an acquisition of immuno-oncology company Forty Seven Inc. for $4.9 billion, and a three-year research collaboration with Onko-innate in which the biotech received an undisclosed upfront payment. There have also been recent reports that Gilead is considering a stake in Arcus Biosciences Inc., another cancer therapy developer.
The company’s well-known HIV drug portfolio, which made up 74% of total sales last year, got a boost with the 2018 approval of Biktarvy, which brought in $4.7 billion in 2019, up from $1.9 billion in 2018. The drug is on track for $6.8 billion in sales this year, according to a FactSet consensus. And while some analysts have raised questions about how shelter-in-place orders will impact prescription drug sales, “for the most part growth brands are still growing (Biktarvy, Dupixent, Aimovig),” Bernstein analysts wrote on Monday.
ENZC is an answer to Gilead toxicity problems and they can continue to make billions except they would have to share some of those billions with us.
If not Gilead someone will help bring ENZC products to the market.
It appears to be a when not if situation.
Worth repeating:
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-important-work-support-medical-product-development-address
Our agency has had experience with evolving infectious diseases. Influenza vaccines and diagnostics are often modified each year to address the predicted predominant strains circulating globally. The agency has created and used regulatory processes that facilitate these updates. We will utilize our experience with influenza to help inform a path forward if SARS-CoV-2 variants emerge against which currently authorized vaccines are not sufficiently effective. Similarly, the FDA also has vast experience with HIV developing resistance to antiviral drugs and will follow regulatory pathways to quickly enable new antiviral drug development for resistant virus.
We have already been communicating with individual medical product sponsors to provide information as they evaluate the impact of COVID-19 variants on their products. And as part of our commitment to a public and transparent process, the FDA is developing guidances for diagnostic, therapeutic and vaccine developers to help guide ongoing medical product development.
For therapeutics, particularly virus-targeting monoclonal antibodies, we are considering approaches to help expedite drug development in this key area, including discussing appropriate regulatory flexibilities. We are aware that some of the neutralizing monoclonal antibodies that have been authorized or are under development are less effective against some of the COVID-19 variants that have emerged, and we are working with drug developers to accelerate the evaluation of new antibodies that could be effective against mutations. Relying on our growing experience with this class of drugs, our teams are discussing approaches to the generation and evaluation of pre-clinical, clinical and chemistry, manufacturing and controls data.
For authorized vaccines, our teams are currently deliberating and discussing the types of data needed to support changes in the composition of the vaccine, either through altering the existing vaccine or through the addition of new vaccine component(s), including how sponsors could demonstrate immune response to new variants through streamlined clinical programs that still gather the crucial data the FDA needs to demonstrate effectiveness, but can be executed quickly to gather this data. To be clear, while we continue to develop an understanding of and address any impact of variants on FDA-regulated products, at this time, available information suggests that the authorized vaccines remain effective in protecting the American public against currently circulating strains of COVID-19.
ENZC has so much going on that it is hard to grasp. They have in their arsenal the future of medical care in the way of therapeutic platforms first for HIV and Coronavirus and then for 14+ more viruses.
The future of health
How innovation will blur traditional health care boundaries
The life sciences and health care industry is on the brink of large-scale disruption. In a future of health that’s defined by radically interoperable data, open yet secure platforms, and consumer-driven care, what role will you play?
In our vision of the future of health, we view radically interoperable data, artificial intelligence (AI), and open, secure platforms as central to the promise of more consumer-focused, prevention-oriented care. AI will enable major scientific breakthroughs, accelerating the creation of new therapies and vaccines to fight diseases. AI-enabled digital therapeutics and personalized recommendations will empower consumers to prevent health issues from developing. AI-generated insights will influence diagnosis and treatment choices, leading to safer and more effective treatments. Additionally, intelligent manufacturing and supply chain solutions will ensure the right treatments and interventions are delivered at the exact moment needed by the patient. https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/future-of-health.html?id=us:2ps:3gl:fohc4:awa:lshc:121420:ad3:kwd-472491030708:the%20%2Bfuture%20of%20%2Bmedicine&gclid=CjwKCAiAsaOBBhA4EiwAo0_AnCsF0fPTERNdE4xTI2mbc961uiNTuuR1QoDHglNSC8VOJwNsgqwMIBoC5SoQAvD_BwE
Monoclonal Antibody Techniques
Monoclonal antibodies (mAbs) are monovalent antibodies which bind to the same epitope and are produced from a single B-lymphocyte clone. Monoclonal antibodies are important tools used in biomedical research, in diagnosis of diseases, and in treatment of such diseases as infections and cancer.
What is the value of monoclonal antibody technology?
Monoclonal antibody technology allows us to produce identical antibody molecules in large scale or industrial yields. It should be noted that the emergence of monoclonal antibody technology makes it possible for a variety of applicationsof monoclonal antibodies.
Single B cell antibody technologies
This approach to produce monoclonal antibodies from single human B cells is based on the analysis of the immunoglobulin gene repertoire and reactivity at the single-cell level by the application of reverse transcription-polymerase chain reaction (RT-PCR) and expression vector cloning.
By recognition of selected cell surface markers, individual mouse or human B cells are isolated (e.g., by fluorescence-activated cell sorting), and genes coding for VL and VH fragments are separately amplified by RT-PCR and combined by PCR. For the final production of human mAbs in vitro, H and L chain gene transcripts from each cell are amplified by RT-PCR before cloning and expression in a mammalian system. This method has the virtue of being able to produce many specific human mAbs in a short period. View more about "Single B cell antibody technologies".
https://www.sinobiological.com/resource/antibody-technical/monoclonal-antibody-technology
PLANO, TX / ACCESSWIRE / November 13, 2020 / Enzolytics Inc. (OTC PINK:ENZC) or the "Company" today shared the following update provided by ENZC's Merger target BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics"), resulting from the application of proceeds from the initial funding received on October 26, 2020. The full text of the update is presented below.
https://www.otcmarkets.com/stock/ENZC/news/Enzolytics-Inc-Shares-Current-BioClonetics-Immunotherapeutics-Inc-Update?id=280113
The procedure for producing monoclonal antibodies is also significant and our procedure differs from those used by other pharma companies. In some cases, other pharma companies produce "humanized" rat and mouse monoclonal antibodies where the original antibody affinity and specificity are not maintained, and the chances of immunogenicity are increased. Our methodology also differs significantly from other pharma approaches using the transgenic mouse model [a human immune system which has been "grafted" within a mouse model] having been "vaccinated" with specific and selected purified CoronaVirus Proteins.
In contrast, our model starts with human "immune-B cells", obtained from convalescent individuals who have recovered from the CoronaVirus. The primary distinction of our process for creating fully human monoclonals is the starting point - namely from human "immune-B cells" from humans who have survived successfully from a "natural" CoronaVirus infection. [color=green][/color]From these, we then produce antibodies that target conserved immutable sites on the virus - to avoid "virus escape".[/color]
Additionally, our antibodies retain the original natural antibody affinity and specificity and have lower risk of immunogenicity when used as a therapeutic. They will provide broad-spectrum coverage against viral variants with increased potency, stability as a single-domain molecule, and, in the recombinant form, will have accessibility to the virus epitopes (binding sites) not accessible with a whole antibody.
PLANO, TX / ACCESSWIRE / December 14, 2020 / Enzolytics, Inc. (OTC:ENZC, Company", )) has engaged SAMM SOLUTIONS, INC. (DBA BTS Research), through a Master Service Agreement ("MSA"), to conduct a toxicity study on the Company's Flagship compound ITV-1. The Company has previously tested the compound in successful Clinical Trials in Bulgaria, but FDA regulations require separate Toxicity tests before an Investigational New Drug process may begin in the United States. https://marketwirenews.com/news-releases/enzolytics-inc-engages-bts-research-to-conduct-toxic-6758170663840334.html
The toxicity test is a non-issue as we already know the expected results from the Annual Report and other documented data:
ITV, produced by Enzolytics, Inc. is a brand-new specific protein for the treatment of HIV and other viral infections. For the first time a naturally occurring strong binding with gp41 HIV-1 envelope protein “in vitro” was demonstrated.
Current market sales indicate that the majority of products show annual sales of 100 plus million, with a significant number ranging from 300 million up to 1 billion dollars in annual sales. Many of the major drug companies, have entered into partnership agreements with newcomers, or with companies in different stages of development in the research pipeline, combining current ARVs with new drug families that impact the HIV/AIDS virus through different mechanisms of action. Partnerships of this nature are a direct result of the major seven Pharmas who control a market with a potential of reaching over $ 15 billion in year 2018, prevent their control and stake in the market share from sliding, due to numerous issues, among which it is important to note, compliance to the drug regimen, adverse reactions to their chemotherapeutic agents impacting the human organs, cost, and eventual viral resistance.
In summation our product’s differentiation is based on:
1- Minimal and minor side effects
2- Zero toxicity issues
3- Tremendous cost savings
4- Short and limited treatment cycle
5- Easier Compliance adherence
6- Zero risk of viral resistance and mutation
The only reason the toxicity study is being done is the FDA requires it. Once it is completed ENZC can submit an Investigational New Drug (IND) application.
The IND application must contain information in three broad areas: Animal Pharmacology and Toxicology Studies - Preclinical data to permit an assessment as to whether the product is reasonably safe for initial testing in humans. Also included are any previous experience with the drug in humans (often foreign use).
I expect no press release on the toxicity study however I expect a release when the IND application is submitted.
Also I don’t expect a press release on the website because once it is up and running there is no reason to tell us as we will already know.
https://twitter.com/SportsCardsTVMe/status/1361002549608931328
https://twitter.com/drgauravchandra/status/1361006189249757187?s=19
COLLEGE STATION, TX / ACCESSWIRE / February 1, 2021 / Enzolytics, Inc. (OTC PINK:ENZC)(the "Company") today announced it has identified seven additional conserved, expectedly immutable sites on the HIV virus against which it plans to produce targeted anti-HIV monoclonal antibodies. The Company's primary anti-HIV monoclonal antibody targets one conserved site on the HIV virus, which site is 98% conserved (either directly or by way of conservative amino acid substitutions) over all 87,336 HIV isolates which have now been curated (analyzed) by the Company using Artificial Intelligence (AI). Additional conserved target sites (some with 98% conserved sequences) have now been identified against which fully human anti-HIV monoclonal antibodies will be produced in its lab on the campus of Texas A&M University in the University's Institute for Preclinical Studies. The significance of producing multiple monoclonal antibodies targeting multiple conserved sites is recognized by experts as a critical approach to effective therapy. This allows the administration of a "cocktail" of antibodies, all targeting conserved and expectedly immutable sites.
The Company is also applying Artificial Intelligence [AI] to scan the hundreds of thousands of isolates that exist in 14 other prevalent viruses, ranging from influenza to Rabies to Ebola. Using the Company's proprietary technique for producing fully human monoclonal antibodies directed against these infectious diseases, the Company will produce multiple neutralizing monoclonal antibodies against these viruses. The significance of this approach is well recognized by experts in virology due to the ability of all viruses to mutate and render ineffective initially developed therapeutics.
Production of the Company's primary anti-HIV monoclonal antibodies is underway at Genscript Labs. Testing of these newly produced monoclonal antibodies is scheduled for early 2021 at the University of Strasbourg in Strasbourg France. Thereafter, Macaque trials are planned at the California National Primate Research Center, Univ. of California, Davis, CA.
Additional information on the progress and Company facilities will be part of the new Company website expected to be rolled out in the coming days.
Quote:
CEO Charles Cotropia stated, "The Company is making significant progress on both of its therapeutic platforms: first, on the identification of prime target sites on both the CoronaVirus and the HIV virus and the creation of neutralizing antibodies directed against these sites, and second, on advancing its ITV-1 peptide therapeutic for patient application in the EU."
Quote:
CSO Harry Zhabilov stated, "With the Bulgarian Drug Administration joining the European Medicine Agency and being recognized under the Mutual Recognition Agreement with the FDA, once we have successfully finished the permitting process the Company will be able to pursue FDA approval for ITV-1. We are currently investigating the required steps but feel confident that this is a viable option for the ITV-1 patented therapy."
https://marketwirenews.com/news-releases/enzolytics-announces-the-discovery-of-seven-newly-id-7491922242125190.html
ENZC have accomplished many milestones to get their products to the marketplace. We come a long way in a short period of time however much more work is necessary and unforeseen circumstances to overcome such as the situation in Bulgaria. Getting our first product to the marketplace is a priority as it is needed and will be done as soon as possible. Whether that is weeks or months away is not only up to the company but also any requirements set forth by regulatory agencies as we have seen with the toxicity test. ENZC is fortunate to be at the The Texas A&M Institute for Preclinical Studies (TIPS)
Quote:
TIPS provides translational researchers with unique access to expertise in all major medical and scientific disciplines including surgery, biomedical engineering, advanced imaging, pathology, radiography, interventional cardiology, neurology, animal behavior, chemistry and engineering. This direct association with the College of Veterinary Medicine and Biomedical Sciences gives researchers the ability to pursue knowledge in a top research university, where cutting-edge technology and scientists at the head of their field can be accessed.
ENZC priority for obvious reasons is the monoclonal antibodies for HIV and CoronaVirus.
FDA is considering all possibilities by any means that can shut Covid-19 down or keep it in check. ENZC technology can certainly help in this process. It is only a matter of time when we find out just how involved we are either leading the charge or part of a collaboration with another company.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-important-work-support-medical-product-development-address
For therapeutics, particularly virus-targeting monoclonal antibodies, we are considering approaches to help expedite drug development in this key area, including discussing appropriate regulatory flexibilities. We are aware that some of the neutralizing monoclonal antibodies that have been authorized or are under development are less effective against some of the COVID-19 variants that have emerged, and we are working with drug developers to accelerate the evaluation of new antibodies that could be effective against mutations. Relying on our growing experience with this class of drugs, our teams are discussing approaches to the generation and evaluation of pre-clinical, clinical and chemistry, manufacturing and controls data.
They are already working on 14 more prevalent viruses that they will eventually produce monoclonal antibodies to combat them.
The work ENZC is accomplishing is neither easy or quick however with the previous research and trials that have already taken place along with the laboratory at TIPS will certainly help in the process. There may be long stretches without press releases as the company works through the necessary processes to get their products to the marketplace. Patience is key and as long as Charles and team members take care of business everything else will fall into place as we have seen thus far.
Charles will release news when he has something to share.
Always have and Always will!
Remember two things.
First and foremost CHARLES is in Charge
Second and very important from the Press Release dated October 19, 2020:
All of our steps are taken with two objectives in mind. First our focus is on creating successful therapeutics against infectious diseases, including HIV and now our focus on the Coronavirus. Secondly, our efforts are also intended to increase the value of our technology and the value of our company - which directly translates into value for our investors. Please know that these are our two guiding objectives with every effort we make.
The link below has all ENZC Press Releases:
https://marketwirenews.com/stock/enzc/news/
The toxicity test is a non-issue as we already know the expected results from the Annual Report and other documented data:
ITV, produced by Enzolytics, Inc. is a brand-new specific protein for the treatment of HIV and other viral infections. For the first time a naturally occurring strong binding with gp41 HIV-1 envelope protein “in vitro” was demonstrated.
Current market sales indicate that the majority of products show annual sales of 100 plus million, with a significant number ranging from 300 million up to 1 billion dollars in annual sales. Many of the major drug companies, have entered into partnership agreements with newcomers, or with companies in different stages of development in the research pipeline, combining current ARVs with new drug families that impact the HIV/AIDS virus through different mechanisms of action. Partnerships of this nature are a direct result of the major seven Pharmas who control a market with a potential of reaching over $ 15 billion in year 2018, prevent their control and stake in the market share from sliding, due to numerous issues, among which it is important to note, compliance to the drug regimen, adverse reactions to their chemotherapeutic agents impacting the human organs, cost, and eventual viral resistance.
In summation our product’s differentiation is based on:
1- Minimal and minor side effects
2- Zero toxicity issues
3- Tremendous cost savings
4- Short and limited treatment cycle
5- Easier Compliance adherence
6- Zero risk of viral resistance and mutation
The only reason the toxicity study is being done is the FDA requires it. Once it is completed ENZC can submit an Investigational New Drug (IND) application.
The IND application must contain information in three broad areas: Animal Pharmacology and Toxicology Studies - Preclinical data to permit an assessment as to whether the product is reasonably safe for initial testing in humans. Also included are any previous experience with the drug in humans (often foreign use).
I expect no press release on the toxicity study however I expect a release when the IND application is submitted.
Texas A&M University
BIOSCIENCE BUSINESS ACCELERATOR
If you represent an emerging life science technology company, this is your opportunity to collaborate with a top-tier research university and establish your presence on campus, in our dedicated Business Accelerator space.
Speed Up the Commercialization Process
By leasing space in the Texas A&M Bioscience Business Accelerator, located in the Texas A&M Institute for Preclinical Studies (TIPS) facility, you will maximize your access to comprehensive research services and product development support—from inception through clinical trials.
Standard Lease Terms
Standard leasing terms are available for one year of occupancy, with the possibility of annual renewal for two additional years at modest rate increases. Annual renewal consideration is subject to tenants achieving mutually-agreeable technical and business development milestones during their previous lease term.
Business and technology services are designed to allow tenants to graduate from the accelerator within three years. Graduates are encouraged to expand operations into available space in the adjacent Texas A&M University Research Park.
Rental rates are variable based on the growth stage of the applicant and level of engagement between the applicant and the A&M System. Preference will be given to new business ventures and to those companies actively engaging the Texas A&M research community.
Included with Lease
• Office furnishings
• Use of conference rooms and auditorium
• Utilities (excluding any special utility needs)
• Secure key access
• Shared reception services
• Janitorial services
• Use of kitchen and dining area
• Mailbox with dedicated street address
Evaluation Criteria
Tenants are selected based on anticipated growth and potential to provide economic benefits to Texas and the Research Valley, as well as create opportunities for members of the A&M System; Texas A&M faculty, researchers, and students; and local businesses.
Applications are evaluated on the following criteria:
• Legal status
• Biotechnology-based product or service
• Growth potential/economic benefits
• Business plan
• Physical requirements
• Financial capacity
https://vpr.tamu.edu/a-m-research/factsheets/pdfs/bioscience-business-accelerator
TWEETS discovered TWEETS uncovered
ENZC mentioned using AI to help identify conserved , immutable targets against HIV virus and the SARs-Cov-2 virus in their 2020 year end update. In just about a month later on February 1, 2021 ENZC announces in a press release it has identified seven additional conserved, expectedly immutable sites on the HIV virus against which it plans to produce targeted anti-HIV monoclonal antibodies. In the same release they and I quote:
Quote:
Additionally, the Company's Genetics and Molecular Biology data science team is now screening (using Computer analysis/Artificial Intelligence [AI]) more than 275,000 CoronaVirus isolates now known, to also identify conserved sites which expectedly are immutable. From this information, anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies will be produced.
Then comes the TWEETS:
So we have a tweet from February 18, 2021 mentioning going one step beyond, AI, abrogate the harmful effects of the variations of mutations and COVID-19.
Then on February 21, 2021 we have a tweet mentioning emergence of variants of concern, concerns with Vaccine effectiveness in the face of viral mutations, groundbreaking solution, big news coming up next week, mutations, AI, patents, innovation and monoclonal antibody.
Then on March 8, 2021 yet another TWEET:
Enzolytics continues its onward and upward march towards strategic partnerships and a stronger Intellectual Property portfolio.
#ENZC #HIV #COVID19 #AI #Gileads #EliLilly #Patent #Monoclonal #Antibodies #acquisition #partnership #immunome
So the tweets make sense because in the February 1, 2021 PR ENZC said and I quote:
Quote:
Additionally, the Company's Genetics and Molecular Biology data science team is now screening (using Computer analysis/Artificial Intelligence [AI]) more than 275,000 CoronaVirus isolates now known, to also identify conserved sites which expectedly are immutable. From this information, anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies will be produced.
Supporting DATA:
Our new lab is being opened on the campus of Texas A&M University in the University's Institute for Preclinical Studies. Here we will expand our development capabilities for the production of additional monoclonal antibodies targeting immutable sites on the HIV and SARS-CoV-2 viruses. In addition to those primary targets on these viruses already known to us, we have engaged an artificial intelligence (AI) and genetics and molecular biology data science team to curate the thousands of isolates (strains) now known as existing in both the HIV virus and the SARS-CoV-2 virus. This process will allow us to identify conserved, immutable targets against which monoclonal antibodies are to be produced.
The significance of this step is well recognized by experts in virology due to the ability of all viruses to mutate and render ineffective, initially developed therapeutics. We have all now heard of the new variants of the CoronaVirus that have just surfaced this week in the United Kingdom and South Africa. Such variants have been found to now exist in the U.S. Due to mutation, these variants have slightly different structures from the virus as initially introduced into the U.S. and will require different therapeutics to address them. The necessary response to such mutations is to identify sites on the virus that do not mutate - that are immutable - and to produce monoclonal antibodies targeting these immutable sites. Using artificial intelligence, we expect to be able to identify these sites such that antibodies may be produced targeting them. This is one of our focuses.
https://marketwirenews.com/news-releases/enzolytics-inc-2020-year-end-update-6713954951124293.html
COLLEGE STATION, TX / ACCESSWIRE / February 1, 2021 / Enzolytics, Inc. (OTC PINK:ENZC)(the "Company") today announced it has identified seven additional conserved, expectedly immutable sites on the HIV virus against which it plans to produce targeted anti-HIV monoclonal antibodies.
The Company's primary anti-HIV monoclonal antibody targets one conserved site on the HIV virus, which site is 98% conserved (either directly or by way of conservative amino acid substitutions) over all 87,336 HIV isolates which have now been curated (analyzed) by the Company using Artificial Intelligence (AI). Additional conserved target sites (some with 98% conserved sequences) have now been identified against which fully human anti-HIV monoclonal antibodies will be produced in its lab on the campus of Texas A&M University in the University's Institute for Preclinical Studies. The significance of producing multiple monoclonal antibodies targeting multiple conserved sites is recognized by experts as a critical approach to effective therapy. This allows the administration of a "cocktail" of antibodies, all targeting conserved and expectedly immutable sites.
Additionally, the Company's Genetics and Molecular Biology data science team is now screening (using Computer analysis/Artificial Intelligence [AI]) more than 275,000 CoronaVirus isolates now known, to also identify conserved sites which expectedly are immutable. From this information, anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies will be produced.
The significance of producing monoclonal antibodies against conserved target sites on targeted viruses is made evident by the mutant strains of the CoronaVirus currently surfacing in the U.S, South Africa, Brazil, United Kingdom and around the world. The same virus mutation exists with HIV, as well as other well-known viruses. As a virus mutates, a therapeutic becomes ineffective when it neutralizes by attacking a site that changes. By targeting an immutable site, a therapeutic is not affected by the mutation. This is well understood by the necessity to produce a new flu vaccine with each flu season, namely because the flu virus mutates. Producing therapeutics that target a conserved site on viruses makes possible the production of a therapeutic that is not rendered ineffective by virus mutation, and therefore can be applied successfully both universally around the world and durably over time.
https://marketwirenews.com/news-releases/enzolytics-announces-the-discovery-of-seven-newly-id-7491922242125190.html
At Enzolytics, we go one step beyond by applying Artificial Intelligence to abrogate the harmful effects of the variations that might be more transmissible; more lethal than merely just "monitoring" and "identifying" the virus mutations.#ENZC#COVID-19
1:28 PM · Feb 18, 2021·Twitter Web App
With the emergence of variants of concern and concerns with Vaccine effectiveness in the face of viral mutations, Enzolytics comes up with a groundbreaking solution. Big news coming up next week. #SARS-CoV2 #mutations #AI #patents #innovation #monoclonalantibody #enzc
3:03 PM · Feb 21, 2021·Twitter Web App
ENZC has used AI to advance/expedite the production of Monoclonal Antibodies.
ENZC is still at the ground floor with the foundation set, the cornerstone in place and is building a solid company that will rival, challenge and change the landscape of the pharmaceutical world in a way that has never be seen before.
A signal to BIG PHARMA/Government that ENZC has the goods to lock down the Coronavirus.
Now the ball is in BIG PHARMA/Government court and the question is "who is gonna pay ball with ENZC?
ENZC possess a must have solution.
This is not a situation of keep the small company down.
This is a situation is how quickly can we get this on the street and "we" is not just ENZC. Now that this information is in the news feeds, people in "high places" will have to step in and get this moving like at warp speed haha.
Seriously though if those in power don't get this moving and there is a bad turn with the coronavirus shame on them. They know the current therapeutics are limited.
The information in the press release says it all:
The Company has always emphasized the need for therapeutics that target conserved and expectedly immutable virus sites - whether the therapeutics is a monoclonal antibody or a preventative vaccine. There is agreement among experts that multiple neutralizing antibodies is critical to effective control of viruses such as the Coronavirus. Recognizing this necessity, if a site is 99% conserved (exits in all 99% of the 50,512 Coronavirus isolates curated), then it can be expected that the next 50,512 variations will also contain the conserved sites. Targeting these conserved sites allows the production of a therapeutic that will not become ineffective due to mutation of the virus. In other words, even a "variant form of the virus" will expectedly contain the immutable targeted sites. Targeting those immutable sites avoids the ineffectiveness that is experienced when a therapeutics or vaccine targets a site that has mutated.
Variant have arisen in viruses other that the Coronavirus. Prior government funding in producing anti-HIV monoclonal antibodies have failed due to what the industry calls "virus escape". The anti-HIV monoclonal antibodies VRC01 and VRC02 produced by Vaccine Research Center in conjunction with the NIH were tested for years and then abandoned due to "virus escape". The Company's focus is on producing monoclonal antibodies that target immutable sites to avoid "virus escape".
New press releases in the making to let the shareholders know who are the
PARTNERSHIPS and what the AQUISITION is all about.
Who Who Who
The float will be updated in the very near future when the 2020 annual report is released.
You can't HANDLE the truth!!!!
There is no LIMIT for ENZC stock price appreciation!!!
Too much going on with ENZC.
The company could drop press release any time that WILL send the stock past all previous HIGHS!
FACTS we KNOW:
1. AI
2. Monoclonal Antibodies being produced
3. Toxicity study results imminent
4. 19+ Patents
5. 2020 Annual Report imminent
6. PCOAB for 2019 and 2020 expected next month
7. The application for OTCQB is being prepared for submission upon issuance of the Audited Statements
8. Charles is in Charge
What we don't know:
1. Relationship to Gileads?
2. Relationship to Eli Lily?
3. Relationship to Immunome?
4. Acquisition?
ENZC has used AI to advance/expedite the production of Monoclonal Antibodies.
ENZC is still at the ground floor with the foundation set, the cornerstone in place and is building a solid company that will rival, challenge and change the landscape of the pharmaceutical world in a way that has never be seen before.
Enzolytics continues its onward and upward march towards strategic partnerships and a stronger Intellectual Property portfolio.
#ENZC #HIV #COVID19 #AI #Gileads #EliLilly #Patent #Monoclonal #Antibodies #acquisition #partnership #immunome
The Company is actively progressing to produce monoclonal antibodies against many other viruses. The proprietary methodically used by the Company will be employed to produce monoclonal antibodies against numerous other virus and using "AI", the Company is curating the know sequences of the following viruses and intends to both seek patent coverage and produce monoclonal antibodies targeting conserved sequences These viruses include:
HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA). Patent applications will be filed claiming the inventive findings. Patent claims will cover the discovered epitope/antigens, with proposed vaccine claims, antibody claims, and related prophylactic/therapeutic method claims relating to these identified epitope/antigens.
FACTS we KNOW:
1. AI
2. Monoclonal Antibodies being produced
3. Toxicity study results imminent
4. 19+ Patents
5. 2020 Annual Report imminent
6. PCOAB for 2019 and 2020 expected next month
7. The application for OTCQB is being prepared for submission upon issuance of the Audited Statements
8. Charles is in Charge
What we don't know:
1. Relationship to Gileads?
2. Relationship to Eli Lily?
3. Relationship to Immunome?
4. Acquisition?
ENZC has used AI to advance/expedite the production of Monoclonal Antibodies.
ENZC is still at the ground floor with the foundation set, the cornerstone in place and is building a solid company that will rival, challenge and change the landscape of the pharmaceutical world in a way that has never be seen before.
Enzolytics continues its onward and upward march towards strategic partnerships and a stronger Intellectual Property portfolio.
#ENZC #HIV #COVID19 #AI #Gileads #EliLilly #Patent #Monoclonal #Antibodies #acquisition #partnership #immunome
The Company is actively progressing to produce monoclonal antibodies against many other viruses. The proprietary methodically used by the Company will be employed to produce monoclonal antibodies against numerous other virus and using "AI", the Company is curating the know sequences of the following viruses and intends to both seek patent coverage and produce monoclonal antibodies targeting conserved sequences These viruses include:
HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA). Patent applications will be filed claiming the inventive findings. Patent claims will cover the discovered epitope/antigens, with proposed vaccine claims, antibody claims, and related prophylactic/therapeutic method claims relating to these identified epitope/antigens.
Yep
As the stock grinds higher and higher
ENZC grinds through their processes time and time again.
Charles said it will take some time and as long as they are successful along the way the stock price will be moving successfully with their goals.
Results from the company will drive the stock price.
The stock price has already hit the 90s with the information we have thus far so 50 is a no-brainer.
Charles said it all:
CEO Charles Cotropia stated: "While we recognize that the production of the therapeutics, we are creating takes time, we have immediately taken the necessary steps to protect our discoveries using U.S. and foreign patents. As a small biotech, this puts us on the same stage as big pharma. We also convey to our supporters our intent to progress as quickly as possible but recognize that accomplishing our goals will take time and effort - but progress and success will be achieved."
Congress is very aware of a lot of people are not in need of the stimulus. They wanted a certain amount of money pushed into the economy with the hopes that it is spent to help stimulate the economy. As far as people wanting handouts has nothing to the stimulus. This is a tool used by governments around the world. People don't choose whether they get the money or not, it is determined by the formula set by the government. My family have worked throughout the pandemic and have used the stimulus money to support or local business especially restaurants who have been hit particularly hard.
The Company has recently confirmed plans to test its monoclonal antibodies at the University of Strasbourg, France, under the direction of Dr. Christiane Moog, Ph.D., Research Director at INSERM, University of Strasbourg, a leading specialist in conducting the preferred PBMC based in vitro neutralization assays protocol for anti-HIV monoclonal antibodies. Additional testing of the Company's antibodies is also being planned at San Raffaele Scientific Institute, Milan, Italy, under the direction of a further expert in the field, Dr. Gabriella Scarlatti, M.D., Ph.D., Head of Viral Evolution and Transmission Unit at San Raffaele Scientific Institute.
https://marketwirenews.com/news-releases/enzolytics-inc-completes-merger-with-bioclonetics-im-6221763307794930.html
In Brazil, a variant of SARS-CoV-2 (known as P.1) emerged that was first was identified in four travelers from Brazil, who were tested during routine screening at Haneda airport outside Tokyo, Japan. This variant has 17 unique mutations, including three in the receptor binding domain of the spike protein. This variant was detected in the US at the end of January 2021.
https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scientific-brief-emerging-variants.html#:~:text=In%20Brazil%2C%20a%20variant%20of,domain%20of%20the%20spike%20protein.
Happy Days are Here Again
Good question on who bought 108 million shares (5% of unrestricted shares) however another question to ponder is who holds the other 1.9 billion shares (95% of unrestricted shares) that wasn't traded.
We know there was plenty of retail buyers just by the comments on the board.
As bad as the pullback was it was a minimal as to the over share count and when it reverses to the upside there will be less shares for sale until the share price recovers to the 50-60 cent.
UPDATE: Dow slides 460 points, Nasdaq sees correction after Powell struggles to cool bond-market jitters
Today 1:37 PM ET (MarketWatch)Print
By Sunny Oh and Mark DeCambre
The 10-year Treasury note yield rose above 1.50%
Stock benchmarks on Thursday fell for a third day as Federal Reserve Chairman Jerome Powell said he was monitoring the recent rise in bond yields but that the rise in inflation expected this year was unlikely to last and current monetary policy remained appropriate.
How are stock benchmarks performing?
On Wednesday (https://www.marketwatch.com/story/dow-futures-climb-over-200-points-ahead-of-private-sector-jobs-report-11614775771?mod=market-snapshot), the Dow fell 121.43 points, or 0.4%, to close at 31,270.09, the S&P 500 shed 50.57 points, 1.3%, ending at 3,819.72, while the Nasdaq Composite Index slid 361.04 points, or 2.7%, to mark its largest two day percentage decline since Tuesday, September 8, 2020.
What's driving the market?
At The Wall Street Journal Jobs Summit, Powell said he would be concerned about a disorderly move in the bond market (https://www.marketwatch.com/story/powell-sends-warning-to-markets-that-fed-doesnt-want-persistent-tightening-in-financial-conditions-11614879804?mod=mw_latestnews), but suggested that it had not had a material impact on financial conditions yet. This comes after previous remarks by Fed officials that they were not overly concerned about the move up in bond yields.
"Powell is echoing a lot of the comments we've heard from other Fed officials in recent days," wrote Mark Grant, chief global strategist at B. Riley Financial.
His remarks did not help markets though as investors had fretted that if Powell shrugged off the recent rise in bond yields, it could spur further selling in a vulnerable Treasurys market and, in turn, weigh on equities.
The 10-year U.S. Treasury note (https://www.marketwatch.com/story/u-s-treasury-yields-edge-lower-as-powell-speech-draws-focus-11614863892?mod=bond-report) rose to 1.54%, up around 7 basis points from where it traded at the end of Wednesday and the highest levels in about a year.
Powell's comments mark the last from Fed officials before a self-imposed "blackout" period ahead of the next two-day policy meeting starting on March 16.
Some of the volatility on Thursday also reflected a "great rotation" as some analysts describe a shift out of highflying technology stocks, viewed as expensive by some measures, to other areas of the market considered undervalued, including energy and financials.
Analysts say the move reflects how investors are pricing in economic recovery and better times for stocks hit in the past year by the COVID-19 pandemic, reversing some of the gains from technology stocks that thrived under business lockdowns and social-distancing protocols last year.
Stocks had initially traded relatively strongly after initial jobless claims in for the week ended Feb. 27 rose 9,000 to 745,000 (https://www.marketwatch.com/story/u-s-unemployment-claims-rise-slightly-to-745-000-after-texas-power-outages-11614865793?mod=mw_latestnews) which was a smaller rise than the 750,000-760,000 estimates expected by economists surveyed by Econoday and Dow Jones. And new federal jobless claims totaled 436,696 in the week.
Beyond the weekly jobless claims data, a reading of productivity and costs showed that U.S. productivity tapered off less than previously estimated at end of 2020 (https://www.marketwatch.com/latest-news?mod=newsviewer_click).
Separately, U.S. factory orders rose (https://www.marketwatch.com/story/us-factory-orders-increase-26-in-january-2021-03-04?mod=mw_latestnews)2.6% in January as manufacturers continued to lead the way for the U.S. economic recovery. Orders for durable goods made to last at least three years climbed an unrevised 3.4% last month. Orders for nondurable goods such as clothing and groceries rose a slower 1.9%.
The Audits are coming the Audits are coming!
Two
First the end of the year Audit for 2020 by March 31. 2021 or sooner.
COLLEGE STATION, TX / ACCESSWIRE / February 22, 2021
The Audits of the Company's current and prior year Financial Statements are in process and the application for OTCQB is being prepared for submission upon issuance of the Audited Statements. The Company plans to complete the two-year audit as quickly as possible but will file the December 31, 2021 Annual Report Financial Statements pursuant to the OTC Markets Pink Basic Disclosure Guidelines. The Company anticipates filing the financial statements under the Basic Disclosure Guidelines for December 31, 2020 in the coming weeks before the filing deadline of March 31, 2021.
https://marketwirenews.com/news-releases/enzolytics-updates-permitting-progress-in-europe-on--5878735653650831.html
The second Audit is an PCAOB for the last two fiscal years (2019 and 2020).
COLLEGE STATION, TX / ACCESSWIRE / January 11, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today, announced it has accepted a proposal from a Houston based PCAOB Audit firm to Audit the Company's year-end financial statements, subject to the receipt and acceptance of the engagement letter. The proposal covers the 2019 and 2020 calendar years for filing with the OTC Markets.
The Company's current accounting firm, Mallet & Barnes, will continue working with the Company to file the year-end financials for 2020 under the Pink Basic Disclosure Guidelines to ensure the continued timely filing of the required financial information during the initial audit of the Company. Future quarterly filings will be reviewed by the auditing firm.
"We are excited about working with our new auditors and achieving fully reporting status. The Company has been focusing on several fronts on which we have made considerable progress. Administratively, we have achieved our goal of bringing our filings current and expect the yield sign to be lifted eminently. We have engaged the Auditor to issue an audited statement in order to achieve our goal of fully reporting by April, if not sooner.
https://marketwirenews.com/news-releases/enzolytics-inc-engages-pcaob-auditor-for-december-31-7746818055730032.html
‘The bears are getting louder’: These indicators are signaling a stock market pullback
BY
ANNE SRADERS
February 22, 2021 4:46 PM EST
All good things must, eventually, come to an end.
In recent days the S&P 500 has marginally sold off, but with the index still up roughly 75% from the market bottom hit nearly a year ago, some on the Street are starting to get antsy.
As CFRA’s chief investment strategist Sam Stovall puts it, “It’s not a question of ‘if’ but ‘when’ the next meaningful market decline will occur,” he wrote in a Monday note.
That's because there are now multiple indicators signaling a pullback is due.
"The bears are getting louder," Lindsey Bell, chief investment strategist for Ally Invest, suggests to Fortune. That's in part because, as Bell notes, the S&P 500 is "stretched" above its 200-day moving average, even more so than stocks were during the September 2020 peak before selling off.
But that's not necessarily bad. "In the near term, pullbacks are a healthy component of market activity, so I don’t think that would be necessarily a terrible thing," she says, suggesting a 5% or 10% pullback might be in order.
Pullback indicators
One thing the Street has been eyeing as a "catalyst for the much-anticipated correction," notes Stovall, is the recent talk of rising inflation coupled with stronger-than-expected retail sales data and producer price index readings. Indeed, on Monday, the 10-year Treasury yield hit over 1.3% while stocks (sans the Dow) sold off.
While improving data is good for the economy and overall recovery, "for equity valuations, higher rates would reduce the justification for multiples that are extremely elevated in absolute terms but attractive relative to bond and cash yields," analysts at Goldman Sachs wrote in a Feb. 12 report. (Still, they note that it's possible that stocks can "rise alongside higher interest rates as long as the rise in rates is orderly and driven by growth.")
Meanwhile, investors are still fixated on lofty valuations. Next 12 months price/earnings ratios are far above historical averages. Stovall notes "all sectors in the S&P 500 but health care trade at double-digit premiums to their 20-year average NTM P/E ratios," with the S&P 500 currently trading at close to 23 times forward earnings (for context, see FactSet's chart, which was tweeted on Sunday). That's actually down a bit from last year, thanks to a strong fourth-quarter earnings season, but still expensive by historical standards.
Morgan Stanley's chief investment officer, Lisa Shalett, wrote in a Monday note, "Every asset class index that we follow [is] now in the top 5% of valuation for the last 20 years," while "the Buffett Indicator, which is the ratio of total U.S. stock market capitalization to GDP, now registers 147%, dwarfing the prior high of 127% reached in 1999."
All of the recent bullishness and high valuations have made some strategists anxious about "frothy" market sentiment and margin debt levels—when investors borrow money to buy or short stocks. Margin debt is "also at an all-time high, whether compared with the S&P 500 or nominal GDP," notes Stovall. "People are much more willing to borrow to make bets if in fact they’re confident about the outcome," Brad McMillan, chief investment officer at Commonwealth Financial Network, told Fortune last week. That rising level of margin debt, "to me, reflects an unhealthy level of positive expectations," he said.
Elsewhere, CFRA's Stovall also points to the longtime divergence between growth versus value: He notes the "rolling 12-month price change for the S&P 500 growth index minus that for the value index hit an all-time high in Q3 2020, and remains at a level not seen since the early months of the 2000–02 bear market."
All of that is to say that markets may need to cool off soon—though, as plenty of strategists will tell you, there's much to be optimistic about in the long run.
What not to do
There's a common (and here, paraphrased) expression on the Street to describe investor behavior during a selloff: Markets are the only place where, when there's a sale, people run out of the store.
That's the kind of reaction those like Stovall hope investors will avoid. "History reminds us that selloffs should be viewed as annoyances to be prepared for, not overreacted to, and that every pullback, correction, and bear market has eventually recovered," he writes. (To drive that point home, see CFRA's chart, showing bull markets vastly outnumber periods of selloffs.)
Investors should therefore focus on "not letting their emotions become their portfolio’s worst enemy by selling, likely near the bottom," suggests Stovall.
Instead, those like Ally's Bell are optimistic about the overall course of markets for the rest of the year. She argues that 2021 earnings estimates might still be too low, providing room for upside; that consumer savings rates are higher and debt is lower; and the consumer will fuel the release of pent-up demand as the economy recovers later in the year.
That's why, Bell adds, "any sort of pullback would most likely be a buy-on-the-dip type of opportunity."
How Emotion Works on the Stock Market
Emotion is ever present in the stock market. Feelings do not discriminate among amateur and professional investors despite the fact that some people have more practice than others at keeping their emotions in check when making financial decisions. Nonetheless, positive and negative feelings do creep into the stock market and have an effect on stock market performance. These emotional extremes can trigger irrational decision-making that costs investors money, while in some cases joy can actually work to a stock's advantage.
Fear
There is an emotional pain that is associated with financial loss that can cause investors to continue holding losing stocks out of fear. Emotional investing is not limited to the small investor, either. Indeed, investment professionals, such as traders, struggle with emotion -- including fear -- when navigating the stock market, too. Professional traders are often cognizant of their weaknesses, however, and have strategic measures in place to help them control their fear of financial loss.
Bad Decisions
The stock market, by nature, is volatile. This means that stocks can exhibit extreme price swings that can make investors uneasy. Market volatility is blamed for causing investors to make ill-timed, emotional investment decisions instead of using logic, often leading to disappointing results. In the two-decade period beginning in 1992, for instance, emotional investing led investors to earn an average annualized profit of 2 percent, while the broader stock market advanced nearly 8 percent, according to BlackRock.com.
Euphoria
Emotional investing can occur in an individual stock just as well as it can permeate the entire stock market. Euphoria is said to be the emotion that drove the price of technology stock Apple higher by about 75 percent over the course of several months, according to CNBC. Eventually, investors started paying more attention to the company's financial fundamentals than their feelings, which had been driving the price increase, and Apple's stock began a sharp descent of about 10 percent.
Emotional Attachment
Emotional attachment, technically known as an "anchoring bias," can cause investors to continue owning shares of doomed stocks. These feelings of attachment can develop for various reasons, such as placing too much emphasis on a single catalyst that led to the investment decision in the first place. Emotional attachments can also form based on an expectation for a stock to reattain a particular threshold, a steadfast belief that may never materialize. As a result, emotional attachments can cause investors to hold into stocks until they are worth nothing.
UPDATE: Dow attempts to snap 2-session skid as investors watch for Powell
Today 9:43 AM ET (MarketWatch)Print
By Mark DeCambre
Stock benchmarks attempted to snap a two-day skid on opening on Thursday after a report on weekly jobless claims came in slightly better than expected. Investors, however, await a speech by Federal Reserve Chairman Jerome Powell at a noon Wall Street Journal conference, where he might provide further insights about the health of the longer-term health of the labor market and a recent rise in yields.
The three main equity benchmarks are trying to avoid to avoid a third day of losses, which have been attributed to the steady climb in bond yields in recent weeks.
How are stock benchmarks performing?
On Wednesday (https://www.marketwatch.com/story/dow-futures-climb-over-200-points-ahead-of-private-sector-jobs-report-11614775771?mod=market-snapshot), the Dow fell 121.43 points, or 0.4%, to close at 31,270.09, the S&P 500 shed 50.57 points, 1.3%, ending at 3,819.72, while the Nasdaq Composite Index slid 361.04 points, or 2.7%, to mark its largest two day point and percentage decline since Tuesday, September 8, 2020.
What's driving the market?
Initial jobless claims in for the week ended Feb. 27 rose 9,000 to 745,000 (https://www.marketwatch.com/story/u-s-unemployment-claims-rise-slightly-to-745-000-after-texas-power-outages-11614865793?mod=mw_latestnews), a smaller rise than the 750,000-760,000 estimates expected by economists surveyed by Econoday and Dow Jones. And new federal jobless claims totaled 436,696 in the week.
The data come as the "great rotation" is under way as some analysts describe a shift out of highflying technology stocks, viewed as expensive by some measures, to other areas of the market considered undervalued, including energy and financials.
The move has been mostly precipitated by a recent selloff in government bonds, which has pushed yields higher as investors price in economic recovery and better times for stocks hit in the past year by the COVID-19 pandemic, after technology stocks did well from business lockdowns and social-distancing protocols last year.
The 10-year U.S. Treasury note was yielding 1.462%, hanging near where it finished trade last Friday, but still representing around its highest rate this year.
Worries stem from expectations that further fiscal aid from Congress will add fuel to an inflationary fire that some fear may cause a more rapid series of interest-rate hikes by the Fed.
Powell may touch on these growing concerns when he speaks at The Wall Street Journal Jobs Summit (https://www.wsjjobssummit.com/agenda/speakers/968849) at 12:05 p.m. Eastern.
"We suspect Powell will once again try and calm the markets but todays macro news could be challenging for the bond market," wrote Peter Cardillo, chief market economist at Spartan Capital Securities, in a research note, referring to the Fed chair's semiannual testimony in front of congressional lawmakers last week.
"In other words, expect a choppy and volatile market," the analyst said.
So far, central bank officials have said that they aren't overly concerned about the move up in bond yields though they are monitoring it closely. Powell's comments will mark the last from Fed officials before a self-imposed "blackout" period ahead of the next two-day policy meeting starting on March 16.
Meanwhile, investors are watching the progress of negotiations over the Biden administration's $1.9 trillion COVID aid package, after Senate Democrats agreed Wednesday to narrow eligibility (https://www.marketwatch.com/story/heres-who-would-get-another-stimulus-check-as-biden-agrees-to-new-income-limits-11614804009)for some of the direct payments that are part of the proposal.
Beyond claims, a reading of productivity and costs showed that U.S. productivity tapered off less than previously estimated at end of 2020 (https://www.marketwatch.com/latest-news?mod=newsviewer_click). A report on factory orders is set for 10 a.m.
Anything is possible.
If one had millions of shares at a fraction of what the price is today it only makes sense to sell some or all.
Profit is Profit.
UPDATE: U.S. stocks slip as economic data disappoints and bond yields spike
Today 10:20 AM ET (MarketWatch)Print
By Mark DeCambre
U.S. stocks slipped Wednesday morning, led by technology stocks, after weaker-than-expected economic data suggested a more tepid rebound from the COVID-19 pandemic, and as bond yields resumed their upward climb.
How are stock benchmarks performing?
On Tuesday (https://www.marketwatch.com/story/u-s-stock-market-set-to-take-breather-after-best-one-day-rally-in-months-11614688222?mod=market-snapshot), the Dow fell 143.99 points, or 0.5%, to 31,391.52, the S&P 500 slid 31.53 points, or 0.8%, to 3,870.29, while the Nasdaq Composite Index dropped 230.04 points, or 1.7%, to 13,358.79.
What's driving the market?
Markets struck an upbeat tone before the start of Wednesday trade after President Joe Biden said late Tuesday (https://www.marketwatch.com/story/biden-moves-forward-his-timeline-for-when-all-adults-can-be-vaccinated-now-mid-may-01614721386)that the U.S. would have enough COVID-19 vaccines for all Americans adults by the end of May, as he announced that the White House brokered a partnership between Merck & Co. (MRK), and Johnson & Johnson (JNJ) to distribute J&J's one-dose vaccination.
The seven-day average of COVID-19 vaccine doses administered in the U.S. recently hit 1.8 million a day (https://www.wsj.com/livecoverage/covid-2021-03-02?mod=article_inline), the Wall Street Journal reported, based on analysis of Centers for Disease Control and Prevention data. More than 50 million Americans have received at least one dose of a vaccine, representing about 15.3% of the population, according to the CDC. Meanwhile, the U.S. has averaged 65,468 cases a day in the past week, down 19% from two weeks ago (https://www.marketwatch.com/story/coronavirus-tally-global-cases-of-covid-19-top-1148-million-and-us-death-toll-above-516000-2021-03-03).
However, Texas and Mississippi said that would they end mask mandates and reopen businesses (https://www.marketwatch.com/story/despite-advice-from-scientists-and-politicians-texas-gov-greg-abbott-will-lift-covid-19-mask-mandate-01614717673), despite recommendations for caution from public-health professionals, including the CDC, which has warned against complacency.
Separately, Washington lawmakers hashed over a further round of COVID aid, with Democrats negotiating the terms of Biden's $1.9 trillion relief package. That's likely to add to the deluge of government bond issuance.
Investor anxieties have centered on moves in the bond market over the past two weeks, with attention trained on moves in the benchmark 10-year Treasury yield.
"The pace of the rise in interest rates was a bit worrisome," said Will Geisdorf, senior research analyst with Sarasota, Florida-based Allegiant Private Advisors. "I think the market is still kind of digesting that."
Right now, investors are most interested in the question of re-opening the economy, Geisdorf told MarketWatch. Any economic boost from more fiscal aid is already price into the market, he thinks, so the real question becomes, "how quickly do things open back up and how well do we suppress further spread?"
For now, Geisdorf thinks we're in "a pause in the reflation trade. I think rates move higher and stocks can move higher with rates. That's why you've seen the back and forth over the past few weeks."
Federal Reserve Gov. Lael Brainard on Tuesday said that she wasn't concerned about the move in yields, which have weighed on stocks because they imply higher borrowing costs for corporations and individuals, but she did note that she was "paying close attention to market developments (https://www.marketwatch.com/story/feds-brainard-expects-burst-of-inflation-this-year-that-wont-last-11614708031?mod=the-fed)."
Brainard said that the economy could see a burst in inflation but said that any such rise would be transitory and due to bottlenecks of supply against a surge in demand as the economy attempts to normalize from social-distancing protocols.
Meanwhile in U.S. economic data, ADP's private-payroll data for February showed 117,000 jobs (https://www.marketwatch.com/story/u-s-private-payrolls-increased-by-sluggish-117-000-in-february-adp-says-11614778023?mod=mw_latestnews)were created in the month, below the 225,000 forecast from economists polled by Dow Jones, and compared with a revised 195,000 in January. The ADP data come ahead of the more closely followed nonfarm-payrolls report due on Friday from the U.S. Labor Department.
The IHS Markit US services sector purchasing managers index rose to 59.8 in February, up from 58.3 in January and above the earlier 'flash' figure of 58.9. However, the Institute of Supply Management non-manufacturing sector index fell to 55.3 from 58.7.
The Beige Book, the Fed's report on business conditions in its districts, will be released at 2 p.m.
Meanwhile, a number of Fed speakers are set to talk Wednesday, including Philadelphia Fed President Patrick Harker at 10 a.m., Atlanta Fed President Raphael Bostic at noon and Chicago Fed President Charles Evans at 2 p.m.
Brazil’s Covid Crisis Is a Warning to the Whole World, Scientists Say
https://www.msn.com/en-us/news/world/brazils-covid-crisis-is-a-warning-to-the-whole-world-scientists-say/ar-BB1ebH5J?ocid=DELLDHP&li=BBnb7Kz
No other nation that experienced such a major outbreak is still grappling with record-setting death tolls and a health care system on the brink of collapse. Many other hard-hit nations are, instead, taking tentative steps toward a semblance of normalcy.
But Brazil is battling a more contagious variant that has trampled one major city and is spreading to others, even as Brazilians toss away precautionary measures that could keep them safe.
On Tuesday, Brazil recorded more than 1,700 Covid-19 deaths, the highest single-day toll of the pandemic.
“The acceleration of the epidemic in various states is leading to the collapse of their public and private hospital systems, which may soon become the case in every region of Brazil,” the national association of health secretaries said in a statement. “Sadly, the anemic rollout of vaccines and the slow pace at which they’re becoming available still does not suggest that this scenario will be reversed in the short term.”
a group of people standing in a garden: Manaus, Brazil, faced a brutal coronavirus outbreak last spring, and was hit hard again early this year. Preliminary studies suggest a new variant is reinfecting people who have already had the virus.© Tyler Hicks/The New York Times Manaus, Brazil, faced a brutal coronavirus outbreak last spring, and was hit hard again early this year. Preliminary studies suggest a new variant is reinfecting people who have already had the virus.
And the news just got worse for Brazil — and possibly the world.
Preliminary studies suggest that the variant that swept through the city of Manaus is not only more contagious, but it also appears able to infect some people who have already recovered from other versions of the virus. And the variant has slipped Brazil’s borders, showing up in two dozen other countries and in small numbers in the United States.
Although trials of a number of vaccines indicate they can protect against severe illness even when they do not prevent infection with the variant, most of the world has not been inoculated. That means even people who had recovered and thought they were safe for now might still be at risk, and that world leaders might, once again, be lifting restrictions too soon.
“You need vaccines to get in the way of these things,” said William Hanage, an epidemiologist at Harvard T.H. Chan School of Public Health, speaking of variants that might cause reinfections. “The immunity you get with your cemeteries running out of room, even that will not be enough to protect you.”
That danger of new variants has not been lost on scientists around the world. Rochelle Walensky, the director of the U.S. Centers for Disease Control and Prevention, pleaded with Americans this week not to let their guards down. “Please hear me clearly,” she said. “At this level of cases with variants spreading, we stand to completely lose the hard-earned ground we’ve gained.”
Brazilians hoped they had seen the worst of the outbreak last year. Manaus, capital of the northern state of Amazonas, was hit so hard in April and May that scientists wondered if the city might have reached herd immunity.
But then in September, cases in the state began rising again, perplexing health officials. An attempt by Amazonas governor Wilson Lima to impose a new quarantine ahead of the Christmas holiday was met with fierce resistance by business owners and prominent politicians close to President Jair Bolsonaro.
By January, scientists had discovered that a new variant, which became known as P.1, had become dominant in the state. Within weeks, its danger became clear as hospitals in the city ran out of oxygen amid a crush of patients, leading scores to suffocate to death.
Doctor Antonio Souza remains haunted by the horrified faces of his colleagues and relatives of patients when it became clear his Manaus hospital’s oxygen supply had been exhausted. He thinks about the patient he sedated, to spare her an agonizing death, when the oxygen ran out at another clinic.
“Nobody should ever have to make that decision,” he said. “It’s too terrible.”
Maria Glaudimar, a nurse in Manaus, said she felt trapped in a nightmare early this year with no end in sight. At work, patients and their relatives pleaded for oxygen and all the intensive care beds were full. At home, her son caught tuberculosis after contracting Covid-19 and her husband shed 22 pounds as he fought the virus.
“No one was prepared for this,” Ms. Glaudimar said. “It was a horror film.”
Since then, the coronavirus crisis has eased somewhat in Amazonas, but worsened in most of Brazil.
Scientists have scrambled to learn more about the variant and to track its spread across the country. But limited resources for testing have kept them behind the curve as they try to determine what role it is playing.
Anderson Brito, a Brazilian virologist at Yale University, said his lab alone sequenced almost half as many coronavirus genomes as all of Brazil had. While the United States has done genetic sequencing on roughly one in 200 confirmed cases, Brazil sequences about one in 3,000.
The variant spread quickly. By the end of January, a study by government researchers found it was present in 91 percent of samples sequenced in the state of Amazonas. By the end of February, health officials had reported cases of the P.1 variant in 21 of 26 Brazilian states, but without more testing it is hard to gauge its prevalence.
Throughout the pandemic, researchers have said that Covid-19 reinfections appear to be extremely rare, which has allowed people who recover to presume they have immunity, at least for a while. But that was before P.1 appeared and doctors and nurses began to notice something strange.
João Alho, a doctor in Santarém, a city in Amazonas, said several colleagues who had recovered from Covid-19 months ago got ill again and tested positive.
Juliana Cunha, a nurse in Rio de Janeiro who has been working at Covid-19 testing centers, said she assumed she was safe after catching the virus last June. But in November, after experiencing mild symptoms, she tested positive again.
“I couldn’t believe it,” Ms. Cunha, 23, said. “It must be the variants.”
But there is no way to be sure what is happening to people who are reinfected, unless both their old and new samples are kept, genetically sequenced and compared.
One way to tamp down the surge would be through vaccinations, but the rollout in Brazil, as in so many countries, has been slow.
Brazil began vaccinating priority groups, including health care professionals and the elderly, in late January. But the government has failed to secure a large enough number of doses. Wealthier countries have snapped up most of the available supply, while Mr. Bolsonaro has been skeptical both of the disease’s impact, and of vaccines.
Just over 5.8 million Brazilians — roughly 2.6 percent of the population — had received at least one dose of a Covid-19 vaccine as of Tuesday, according to the health ministry. Only about 1.5 million had received both doses. The country is currently using the Chinese-made CoronaVac — which laboratory tests suggest is less effective against P.1 than against other variants — and the one made by the British-Swedish pharmaceutical company AstraZeneca.
Margareth Dalcolmo, a pulmonologist at Fiocruz, a prominent scientific research center, said Brazil’s failure to mount a robust vaccination campaign set the stage for the current crisis.
“We should be vaccinating more than a million people per day,” she said. “That is the truth. We aren’t, not because we don’t know how to do it, but because we don’t have enough vaccines.”
Other countries should take heed, said Ester Sabino, an infectious disease researcher at the University of São Paulo who is among the leading experts on the P.1 variant.
“You can vaccinate your whole population and control the problem only for a short period if, in another place in the world, a new variant appears,” she said. “It will get there one day.”
Health minister Eduardo Pazuello, who called the variant a “new stage” of the pandemic, said last week that the government was ramping up its efforts and hopes to vaccinate roughly half of its population by June and the rest by the end of the year.
But many Brazilians have little faith in a government led by a president who has sabotaged lockdowns, repeatedly downplayed the threat of the virus and promoted untested remedies long after scientists said they clearly did not work.
Just last week, the president spoke dismissively of masks, which are among the best defenses to curb contagion, claiming that they are harmful to children, causing headaches and difficulty concentrating.
Mr. Pazuello’s vaccine projections have also been met with skepticism. The government last week placed an order for 20 million doses of an Indian vaccine that has not completed clinical trials. That prompted a federal prosecutor to argue in a legal filing that the $286 million purchase “puts millions of lives at risk.”
Even if it proves effective, it will be too late for many.
Tony Maquiné, a 39-year-old marketing specialist in Manaus, lost a grandmother, an uncle, two aunts and a cousin, in the span of a few weeks during the latest surge of cases. He says time has become a blur of frantic efforts to find hospitals with free beds for the living, while arranging funerals for the dead.
“It was a nightmare,” Mr. Maquiné said. “I’m scared of what lies ahead.”
Manuela Andreoni and Ernesto Londoño reported from Rio de Janeiro and Letícia Casado from Brasília. Carl Zimmer contributed reporting from New Haven, Conn.
What major pharmaceutical company do you contract work for?
UPDATE: Stocks struggle for direction after best one-day rally in months
Today 9:43 AM ET (MarketWatch)Print
By Mark DeCambre and William Watts
U.S. stocks struggled for direction early Tuesday, with major benchmarks seeing a mixed performance after putting in their best daily gains in months during the previous session as global bond yields halted their rise.
How are stock benchmarks performing?
On Monday (https://www.marketwatch.com/story/dow-futures-rise-280-points-to-start-march-as-benchmark-treasury-yield-hangs-around-1-43-11614602421?mod=market-snapshot), the Dow booked its best daily gain since Nov. 9, the Nasdaq Composite Index registered its best day since Nov. 4, while the S&P 500 finished the session with its best daily gain since June 5.
What's driving the market?
Equity markets looked to take a pause a day after upbeat reports on the strength of the economy and a slight pullback in sovereign bond yields provided some support for risky assets as the outlook for the COVID-19 pandemic improves.
Economically sensitive, cyclical sectors like energy and financials continue to outperform the broader market amid optimism about the coronavirus vaccine rollout. (https://www.marketwatch.com/story/coronavirus-tally-global-cases-of-covid-19-top-1144-million-and-us-death-toll-above-514000-2021-03-02)
Last week's rise in bond yields reflected concerns that the distribution of vaccines from the likes of Johnson & Johnson (JNJ) and other drugmakers, as well as a likely imminent infusion of fresh government spending, will drive up inflation as well as economic growth in the second half of 2021.
Investors are hoping to garner more guidance from Federal Reserve speakers, with Fed Gov. Lael Brainard slated to speak at 1 p.m. Eastern and San Francisco Fed President Mary Daly is set to talk at 2 p.m.
"U.S. markets look set for a weaker open after yesterday's sharp rebound ahead of more jawboning from a number of Federal Reserve policy makers later today," wrote Michael Hewson, chief market analyst at CMC Markets, in a daily research note.
Read:After Australia soothes global market worries, will other central bankers step up? (https://www.marketwatch.com/story/after-australia-soothes-global-market-worries-will-other-central-bankers-step-up-11614636109?reflink=mw_share_twitter)
"The most notable will be permanent Fed board member Lael Brainard whose comments last week almost played down market concerns about the sharp moves higher in long term yields," the analyst wrote. "Given recent volatility markets will be looking for a much stronger pushback lest the US central bank loses control of market expectations."
Meanwhile, concerns about bubbles and overvalued parts of the market were a source of concern for Chinese regulators (https://www.marketwatch.com/story/chinas-top-banking-regulator-warns-of-asset-bubbles-on-wall-street-and-elsewhere-11614676238?mod=home-page). Guo Shuqing, chairman of the China Banking and Insurance Regulatory Commission and Party secretary of the central bank warned at a briefing in Beijing that stock values were disconnected with economic fundamentals in the U.S. and Europe, reported Bloomberg News (https://www.bloomberg.com/news/articles/2021-03-02/china-worried-about-bubbles-in-property-foreign-markets?cmpid=BBD030221_MKTEU&utm_medium=email&utm_source=newsletter&utm_term=210302&utm_campaign=marketseurope&sref=J9GPLx1B) and Reuters (https://www.reuters.com/article/us-china-banks/china-studies-measures-to-manage-capital-inflows-amid-global-financial-risk-idUSKBN2AU080?il=0).
Investors were also focused on developments on the vaccine front. President Joe Biden will announce later Tuesday that Merck & Co. Inc. (MRK) will help make Johnson & Johnson's (JNJ) one-shot COVID-19 vaccine in an unusual agreement between two competitors that could lead to a significant boost in supply, the Washington Post reported (https://www.marketwatch.com/story/president-biden-to-announce-later-tuesday-that-merck-with-help-make-jj-vaccine-washington-post-2021-03-02?mod=mw_quote_news) Tuesday.
Looking ahead, markets may focus on Biden's picks to lead the Securities and Exchange Commission, Gary Gensler, and the Consumer Financial Protection Bureau, Rohit Chopra, who will both participate in confirmation hearings (https://www.marketwatch.com/story/meme-stocks-crypto-and-student-loans-what-to-watch-for-at-sec-cfpb-confirmation-hearings-11614621804) before the Senate Banking, Housing and Urban Affairs Committee.
Will ENZC have a partnership/licensing or be bought out?
Don't know.
If they go the partnership/licensing route, we shareholders can grow with the company.
If they are bought out then at what price?
How many BILLIONS?
A cash buy out would be very expensive and highly unlikely if more than 10 dollars a share. I would expect some type of stock swap and a cash deal.
The task at hand would be how do one value ENZC technology?
ENZC is continuing to make progress on their quest to bring products to the market.
We have gotten many updates expectantly and unexpectedly.
The PCAOB is not an easy task and will probably take until April as Charles said if not longer. Doing one yearly audit is tough enough however doing 2 yearly audits isn’t a cakewalk.
ENZC has different avenues available to get the process moving further along:
Coronavirus Treatment Acceleration Program
https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap
FDA Emergency Use Authorization
http://www.ctinmateinfo.state.ct.us/resultsupv.asp
FDA Investigational New Drug (IND) Application
https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application
Operation Warp Speed(if invited)
https://www.defense.gov/Explore/Spotlight/Coronavirus/Operation-Warp-Speed/
Regardless of which avenue ENZC takes continued funding will be necessary for further progress. It could come from grants, dilution (not saying it will just listing it as an avenue), undisclosed partner or through one of the government programs available to fight Covid-19.
ENZC has released a stream of information that suggesting they the ability to provide therapeutic solutions solving the virus escape problem, countering any variants to viruses and doing so with little or no toxicity.
Speaking of toxicity, ENZC is awaiting results from testing that is necessary for them to submit an IND application to the FDA. All information provided thus far from ENZC suggests that have little or no toxicity in their therapeutics so the test result should have a positive impact on the company.
ENZC has done a lot in the past 6 months. We have not been informed yet of very company changing catalysts such as funding, application submissions or results for certain tests. However we had surprises such as the patent applications and setbacks as the Bulgaria situation. ENZC has moved forward and onward regardless of the good, bad and hopefully never ugly situations. They are in a good position to succeed as long as they press forward, are properly funded and keep the pedal to the medal as they have been doing.
UPDATE: Dow struggles as stock market attempts rebound following stimulus-inspired jump in consumer spending
Today 9:49 AM ET (MarketWatch)
By William Watts and Mark DeCambre
Treasury yields pull back as bond selloff takes a breather
Stocks on Friday were trying to find a bullish footing following a sharp selloff triggered by a rise in Treasury yields, which left the tech-heavy Nasdaq Composite on track for the worst weekly skid since October.
What are major indexes doing?
On Thursday (https://www.marketwatch.com/story/stock-futures-mixed-after-dow-returns-to-record-territory-11614256362?mod=market-snapshot), the Dow tumbled just shy of 560 points, or 1.8%, while the S&P 500 dropped 2.4%, leaving both indexes with the biggest one-day declines since late January. The Nasdaq Composite dropped 3.5%, for its biggest one-day drop since October.
For the week, the Dow was headed for a 0.3% loss, the S&P 500 was tracking a 2% decline while the Nasdaq Composite was off 5.4%. That would be the Nadaq's biggest slide since the week ended Oct. 30, according to FactSet data.
What's driving the market?
An acceleration in the Treasury market selloff Thursday sent yields, which move in the opposite direction of bond prices, up sharply, triggering a stock market selloff that hit tech-related stocks particularly hard.
"There was a flash spike in the 10-year yield and that upset the apple cart, as higher yields are spooking the stock market," said Ryan Detrick, chief market strategist at LPL Financial. "Could there be more inflation coming than what most think? Although the Fed isn't worried about that, the market might be."
Read: 3 reasons the rise in bond yields is gaining steam and rattling the stock market (https://www.marketwatch.com/story/3-reasons-the-rise-in-bond-yields-is-gaining-steam-and-rattling-the-stock-market-11614292476)
The yield on the 10-year Treasury note rose 13 basis points Thursday to finish at a more-than-one-year high at 1.51%. Yields pulled back Friday morning, with the 10-year rate down 4.7 basis points at 1.473%.
Rising yields can make bonds more attractive to investors relative to stocks, undercutting the longstanding "there-is-no-alternative" mantra that held that investors seeking yield had few other choices than equities due to ultralow rates on government securities. Shares of tech companies, which tend to be heavier borrowers and have seen the most stretched valuations, are seen as particularly vulnerable to a rise in yields.
Need to Know: So long, there-is-no-alternative trade. What now? (https://www.marketwatch.com/story/so-long-there-is-no-alternative-trade-what-now-11614339217?mod=home-page)
The move in rates had unsettled investors earlier in the week, but market participants were temporarily soothed by testimony from Federal Reserve Chairman Jerome Powell on Tuesday and Wednesday. Powell said the economy remained a long way from recovery and indicated the central bank was committed to waiting until inflation tops its 2% target before moving to begin easing up on its own stimulus efforts.
"Investors clearly have a hard time buying into the Fed speak insisting that it's too early to talk about tapering," said Han Tan, market analyst at FXTM, in a note.
Market participants "are of the opinion that improving U.S. economic conditions will cajole the central bank into tightening their policy settings sooner than expected. Fed funds futures are already pointing to an interest rate hike that's brought forward to the end of 2022, from 2024," Tan said.
On the fiscal policy front, the Senate parliamentarian on Thursday ruled against passing minimum-wage legislation through the budget-reconciliation process.
In economic reports, consumer data showed that Americans increased spending in January for the first time in three months after the government sent $600 stimulus checks to families and boosted unemployment benefits as part of effort to shore up the economy.
Consumer spending jumped 2.4%, the government said (https://www.marketwatch.com/story/stimulus-checks-spark-2-4-surge-in-consumer-spending-and-boost-economy-in-early-2021-11614347500?mod=home-page), marking the biggest increase since last June. Economists polled by Dow Jones and The Wall Street Journal has forecast a 2.5% increase. Incomes, meanwhile, rose by a much larger 10%.
A key measure of inflation, meanwhile, climbed 0.3% last month. The so-called PCE price index is the Federal Reserve's preferred measure of inflation.
Separately, trade data showed (https://www.marketwatch.com/story/u-s-trade-deficit-in-goods-in-widens-slightly-in-january-11614347138) that the U.S. trade deficit in goods widened to $83.7 billion in January from a revised $83.2 billion in the prior month, the Commerce Department said Friday. Imports of goods such as consumer electronics rose 1.1% to $218.9 billion in January. Goods imports were up 8.2% compared with a year earlier. Exports rose 1.4% to $135.2 billion. They are down 0.7% compared with one year ago.
Meanwhile, the Chicago-area purchasing managers index for February is set for release at 9:45 a.m. The University of Michigan's final read on its February consumer sentiment index is set for 10 a.m.
What is going to happen to ENZC Buyout or Partnerships?
There are many things to consider one being just how valuable ENZC is and could a company afford to pay that value if it is very steep.
Rounding up to 2.8 Billion shares the different price valuations are:
2.8 Billion shares at $5 would be 14 Billion Dollars
2.8 Billion shares at $10 would be 28 Billion Dollars
2.8 Billion shares at $20 would be 56 Billion Dollars
2.8 Billion shares at $30 would be 84 Billion Dollars
2.8 Billion shares at $40 would be 112 Billion Dollars
2.8 Billion shares at $50 would be 140 Billion Dollars
2.8 Billion shares at $60 would be 168 Billion Dollars
2.8 Billion shares at $70 would be 196 Billion Dollars
2.8 Billion shares at $80 would be 224 Billion Dollars
2.8 Billion shares at $90 would be 252 Billion Dollars
2.8 Billion shares at $100 would be 280 Billion Dollars
The top 5 pharma M&A deals of 2020
AstraZeneca & Alexion
By far the biggest pharma deal of the year is AstraZeneca’s late-breaking offer to buy Alexion for $39 billion.
Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and with the purchase, AZ will bolster its immunology franchise with $4 billion blockbuster Soliris (eculizumab) and longer acting follow-up Ultomiris (ravulizumab), plus a pipeline of 11 drugs for rare and autoimmune diseases.
Gilead & Immunomedics
The AZ-Alexion deal is likely to be the only big pharma merger this year, but Gilead’s purchase of US biotech Immunomedics and its potential cancer blockbuster Trodelvy isn’t far off it in terms of value, with the deal totalling $21 billion.
California-based Gilead announced its strong intentions in oncology in 2017 with its $11.9 billion buy of Kite Pharma and followed that earlier this year by acquiring immuno-oncology firm Forty Seven for $4.9 billion (see below). Shoring up its assets in a wider range of disease areas will help the company weather the storm as the pool of patients eligible to receive its hepatitis C drugs such as Sovaldi shrinks.
Johnson and Johnson & Momenta
This $6.5 billion deal means that J&J has added potential inflammatory disease blockbuster nipocalimab to the pipeline at its Janssen pharmaceuticals unit.
J&J thinks that Momenta’s lead drug nipocalimab could be a kind of Swiss army knife drug that could be used across a range of inflammatory diseases including maternal-foetal disorders, neuro-inflammatory disorders, rheumatology, and autoimmune haematology.
Gilead & Forty Seven
Further cementing Gilead’s ambitions in cancer, this $4.9 billion deal adds an antibody targeting several blood cancers to the company’s research pipeline.
Forty Seven is based in Menlo Park, a short drive away from Gilead’s base in Foster City, and is developing magrolimab, which is targeting myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML), and diffuse large B-cell lymphoma (DLBCL).
Sanofi & Principia Biopharma
Sanofi added a potential multiple sclerosis drug to its pipeline when it bought Principia Biopharma for up to $3.68 billion in August.
The French pharma paid $100 per share in cash for San Francisco-based Principia, which specialises in Bruton’s kinase (BTK) inhibitor drugs, after the deal was unanimously agreed by both boards of directors.
https://pharmaphorum.com/views-and-analysis/the-top-5-pharma-ma-deals-of-2020/
The biggest pharma merger and acquisition deals of 2019
The pharmaceutical industry saw some notable mergers and acquisitions in 2019; this article lists the top 10 by transaction size.
1. Bristol-Myers Squibb (BMS)/Celgene – $74 billion
BMS successfully acquired Celgene in November of last year, after it gained regulatory approval from all government authorities required.
Initially announced in January 2019, the agreement took 11 months until Celgene became a wholly owned subsidiary of BMS. The deal has widened the company’s pipelines in oncology, haematology, immunology and cardiovascular disease.
2. AbbVie/Allergan – $63 billion
In October 2019, Allergan shareholders voted to approve its acquisition by AbbVie, with over 99 percent of the votes in favour of the decision.
Announced in June, the M&A deal aims to produce new growth platforms and expand the revenue base for both companies.
“In addition to delivering value for shareholders, this combination will create a leading biopharmaceutical company with a diversified portfolio and enhanced opportunity to invest in and deliver innovation for the patients we serve,” said Brent Saunders, Chairman and CEO of Allergan.
The transaction is expected to close in early 2020, subject to customary closing conditions and regulatory approvals.2
3. Takeda Pharmaceutical Company (Takeda)/Shire – $58.6 billion
In January of last year, Takeda announced that it completed its M&A of Shire to expand its global biopharmaceutical capabilities headquartered in Japan.
According to Takeda, its R&D efforts are focused on oncology, gastroenterology, neuroscience and rare diseases, with investment into plasma-derived therapies and vaccines.
At the time, Christophe Weber, President and CEO of Takeda, said: “We are pleased to have completed the acquisition several months earlier than expected, which was enabled through the hard work of our respective organisations and the smooth receipt of regulatory clearances.
“This marks a significant moment in Takeda’s history and is an exciting step forward as we accelerate our transformation journey to deliver highly-innovative medicines.”3
4. Danaher Corporation/General Electric (GE) Biopharma – $21.4 billion
The agreement between Danaher and GE Biopharma was announced in February of last year to expand Danaher’s opportunities in the bioprocessing sector.
The M&A deal will add GE Biopharma’s instruments, consumables and software products to Danaher’s inventory in order to support its biopharmaceutical drug development.
Danaher’s President and CEO, Thomas Joyce, said: “GE Biopharma is renowned for providing best-in-class bioprocessing technologies and solutions.” He added that the acquisition would bring a “highly innovative, industry-leading product suite to our life sciences portfolio, providing an excellent complement to our current biologics workflow solutions.”4
5. Amgen/Rights to Otezla® – $13.4 billion
In August 2019, Amgen announced that it had entered into an agreement with Celgene to acquire the rights to Otezla (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis.
Amgen cited that the rights would accelerate the company’s short- and long-term revenue growth, especially due to its iexclusivity until at least 2028 in the US, as well as worldwide rights.
“Otezla represents an exciting opportunity to strengthen Amgen’s presence in inflammation and continue Amgen’s geographic expansion,” said Robert Bradway, Chairman and CEO at the company. “We are excited about the opportunity that Otezla represents for Amgen, for our shareholders and for patients worldwide.”5
6. Mylan/Upjohn (a division of Pfizer) – $12 billion
Mylan and Pfizer agreed to combine the former company with the latter’s subsidiary Upjohn in July of last year after a unanimous vote from the Board of Directors.
According to the companies, the transaction would accelerate the businesses’ ability to serve patient needs as well as bring Mylan’s portfolio into an alliance with Upjohn’s position in markets such as China.
The companies announced that they would be based in the US, but also operate global centres in China and India.
Robert Coury, Mylan Chairman, said: “The new company, which combines the unique assets of Mylan with the iconic brands of Pfizer’s Upjohn business, will not only accelerate our mission to serve the world’s changing health needs, but also further unlock the true value of our platform while delivering attractive returns to shareholders for many years to come.”6
7. Pfizer/Array Biopharma – $11.4 billion
The definitive merger between Pfizer and Array BioPharma was announced in June 2019 following the approval of the Board of Directors at both companies.
Array’s broad pipeline of targeted cancer medicines in development and its portfolio of potentially best- and first-in-class medicines are expected to expand Pfizer’s future revenue significantly.
“The acquisition of Array strengthens our innovative biopharmaceutical business, is expected to enhance its long-term growth trajectory and sets the stage to create a potentially industry-leading franchise for colorectal cancer alongside Pfizer’s existing expertise in breast and prostate cancers,” said Albert Bourla, CEO of Pfizer.7
8. Novartis/The Medicines Company – $9.7 billion
In November 2019, Novartis announced that it had entered into an agreement and plan of merger with The Medicines Company.
According to Novartis, inclisiran, developed by The Medicines Company, represents a near-term product launch opportunity and is expected to contribute highly to revenues from 2021.
Novartis CEO, Vas Narasimhan, said: “We are excited about entering into an agreement to acquire The Medicines Company as inclisiran is a potentially transformational medicine that reimagines the treatment of atherosclerotic heart disease and familial hypercholesterolaemia… The prospect of bringing inclisiran to patients also fits with our overall strategy to transform Novartis into a focused medicines company.”
The M&A transaction is expected to close in the first quarter of 2020, subject to closing conditions.8
9. Eli Lilly and Company/Loxo Oncology – $8 billion
Eli Lilly and Loxo Oncology entered a definitive agreement for Lilly to acquire Loxo in July 2019, in order to broaden the first company’s cancer treatment options.
“Loxo Oncology’s portfolio of RET, BTK and TRK inhibitors targeted specifically to patients with mutations or fusions in these genes, in combination with advanced diagnostics that allow us to know exactly which patients may benefit, creates new opportunities to improve the lives of people with advanced cancer,” said Dr Daniel Skovronsky, Chief Scientific Officer (CSO) and President of Lilly Research Laboratories.
According to Lilly, the M&A will be the largest in a series of transactions it has completed to broaden its cancer treatment efforts.9
10. GlaxoSmithKline (GSK)/Tesaro – $5.1 billion
In January of last year, GSK successfully completed its acquisition of Tesaro, an oncology-focused company through its wholly owned subsidiary Adriatic Acquisition Corporation.
The agreement transferred Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor, currently approved for use in ovarian cancer, to GSK’s pipeline.
Dr Hal Barron, CSO and President, R&D, GSK, said: “The acquisition of Tesaro, which we have completed today, significantly strengthens our oncology pipeline and brings new scientific capabilities and expertise that will increase the pace and scale at which we can help patients living with cancer.”10
https://www.europeanpharmaceuticalreview.com/article/111051/the-biggest-pharma-merger-and-acquisition-deals-of-2019/
We have the best peer acceptance in the world.
Dr. Anthony Fauci.
He went to court to get our technology.
I don't believe it backfired. The little guys didn't try to teach big wall street a lesson. A big hedge fund bit off more than he could chew and other big wall street firms took his ass down. This wasn't a David versus
Goliath situation. It made for a good story however the real money was made by big institutional firms (100 of millions of dollars) not wallstreetbets although many of them made some nice profits as well.
True
Texas A&M University
BIOSCIENCE BUSINESS ACCELERATOR
If you represent an emerging life science technology company, this is your opportunity to collaborate with a top-tier research university and establish your presence on campus, in our dedicated Business Accelerator space.
Speed Up the Commercialization Process
By leasing space in the Texas A&M Bioscience Business Accelerator, located in the Texas A&M Institute for Preclinical Studies (TIPS) facility, you will maximize your access to comprehensive research services and product development support—from inception through clinical trials.
Standard Lease Terms
Standard leasing terms are available for one year of occupancy, with the possibility of annual renewal for two additional years at modest rate increases. Annual renewal consideration is subject to tenants achieving mutually-agreeable technical and business development milestones during their previous lease term.
Business and technology services are designed to allow tenants to graduate from the accelerator within three years. Graduates are encouraged to expand operations into available space in the adjacent Texas A&M University Research Park.
Rental rates are variable based on the growth stage of the applicant and level of engagement between the applicant and the A&M System. Preference will be given to new business ventures and to those companies actively engaging the Texas A&M research community.
Included with Lease
• Office furnishings
• Use of conference rooms and auditorium
• Utilities (excluding any special utility needs)
• Secure key access
• Shared reception services
• Janitorial services
• Use of kitchen and dining area
• Mailbox with dedicated street address
Evaluation Criteria
Tenants are selected based on anticipated growth and potential to provide economic benefits to Texas and the Research Valley, as well as create opportunities for members of the A&M System; Texas A&M faculty, researchers, and students; and local businesses.
Applications are evaluated on the following criteria:
• Legal status
• Biotechnology-based product or service
• Growth potential/economic benefits
• Business plan
• Physical requirements
• Financial capacity
https://vpr.tamu.edu/a-m-research/factsheets/pdfs/bioscience-business-accelerator
UPDATE: Stocks turn positive, Dow touches intraday high on reopening optimism
Today 11:36 AM ET (MarketWatch)
By William Watts and Andrea Riquier
Tesla shares jump 4% as ARK Invest boosts holdings
Stocks reversed earlier losses to trade mixed, with the Dow Jones Industrial Average touching a fresh intraday record, as optimism about reopening the economy appeared to win out over concerns about surging bond yields.
On Tuesday, testimony from Federal Reserve Chairman Jerome Powell was credited with helping major benchmarks reverse big intraday losses.
What are major benchmarks doing?
The Dow on Tuesday erased a loss of more than 360 points to eke out a positive finish, while the S&P 500 snapped a five-day losing streak and the Nasdaq Composite trimmed a loss of nearly 4% to end the session only 0.5% lower.
What's driving the market?
Bond yields were on the move again Wednesday morning, reversing early gains in stock futures, after the Food and Drug Administration said that Johnson & Johnson's single-dose COVID-19 vaccine candidate has no unexpected safety concerns (https://www.marketwatch.com/story/fda-says-j-js-covid-19-vaccine-has-no-specific-safety-concerns-11614174846), a step that moves the experimental vaccine one step closer to emergency authorization. Signs of an economy that may run hotter than expected are helping drive yields higher.
"I still think good news is good news when it comes to information about vaccines and therapies that are going to help us out of the pandemic," said Brian Vendig, president of Westport, Connecticut-based MJP Wealth Advisors, in an interview with MarketWatch.
"Sometimes good information comes out and markets move down, but we have to keep in mind that the tech sector is 30% of the overall market cap of US equities indices," he said. "News like this is good for the other parts of the market that didn't rally last year."
Even if tech and other megacap stocks sell off, Vendig said, other sectors, like industrials(XLI), materials(XLB), and energy(XLE), should benefit. "It's a little bit of a rotation."
In his remarks Tuesday, Powell said the economy remained far off the Fed's employment and inflation goals (https://www.marketwatch.com/story/feds-powell-says-economy-could-improve-later-this-year-but-sees-no-change-in-policy-11614092422?mod=mw_latestnews), giving no indication a spike in bond yields would prompt the central bank to begin tapering its asset-buying program. Fears the Fed could move to scale back stimulus sooner than anticipated had been blamed for the stock market's recent wobble, which hit highflying, tech-oriented and growth shares hardest, while stocks more sensitive to the economic cycle benefited.
"Powell gave another market-friendly speech, maintaining a highly accommodative stance, almost welcoming the move higher in U.S. bond yields as they 'reflect more confidence in the economy' and seemed unperturbed by the frothy conditions in financial markets," said Chris Weston, head of research at Pepperstone, in a note.
"His views on future asset purchases supported risk, suggesting he wanted to see 'substantial progress' before tapering," Weston said.
Powell is delivering a second day of testimony, this time to a House panel. Other Fed officials set to make public remarks Wednesday include Gov. Lael Brainard, who gave a guest lecture at Harvard, and Vice Chairman Richard Clarida, who will deliver
a speech on the economy to the U.S. Chamber of Commerce at 1 p.m.
https://invest.ameritrade.com/grid/p/site#r=jPage/https://research.ameritrade.com/grid/wwws/markets/news/story.asp?YYY600_4TasO+9+jFjDGVndajH8hBQXDAzYn/E/UN/nGo6LpeQ5VBAiDz2Yh1u1hPxNcBfxw1kwx7WR4m3Fndp40/oPgNLVt6OPUjgm+SoygfD/eAnK+lXFSYyOQmxKnFBOLBLEbCwT92il1Gw=&c_name=invest_VENDOR
Enzolytics Announces the Discovery and Patenting of Eleven Newly Identified Conserved Target Sites on the SARS-CoV-2 Virus (Coronavirus)
Monday, February 22, 2021 10:30 AM
Production of Monoclonal Antibodies Targeting These Sites is in Process in the Company's Texas Lab.
COLLEGE STATION, TX / ACCESSWIRE / February 22, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced it has identified eleven conserved, expectedly immutable sites (epitopes) on the Coronavirus against which it is producing targeted anti-SARS-CoV-2 monoclonal antibodies. Using computer analysis (Artificial Intelligence [AI]), the Company's genetics and molecular biology data science team has now screened more than 50,512 Coronavirus isolates currently known and has identified conserved sites which expectedly are immutable. The 11 conserved sequences identified on the virus isolates curated have been identified on the basis that they are 98.71% to 99.29% conserved over the entirety of the 50,512 Coronavirus isolates analyzed.
Before completing the Artificial Intelligence analysis of the 50,512 SARS-CoV-2 isolates to identify conserved epitopes, the Company's scientists predicted a specific target epitope that is correlative in structure to the site on the HIV virus to which the Company has produced a monoclonal antibody that has been shown to neutralize the HIV virus. The prediction was that this site would be conserved as is the correlative site on the HIV virus. The AI analysis of the 50,512 SARS-CoV-2 isolates identified this predicted site on the virus as 99% conserved across all 50,512 isolates. This primary site on the SARS-CoV-2 virus has also been confirmed as existing (100%) in the U.S. SARS-CoV-2 virus and the virus variants which have surfaced in United Kingdom, Brazil and South Africa, which are now in the U.S. This epitope on the SARS-Cov-2 virus is included in the first being targeted by the Company in its production of epitope specific monoclonal antibodies.
The Company has always emphasized the need for therapeutics that target conserved and expectedly immutable virus sites - whether the therapeutics is a monoclonal antibody or a preventative vaccine. There is agreement among experts that multiple neutralizing antibodies is critical to effective control of viruses such as the Coronavirus. Recognizing this necessity, if a site is 99% conserved (exits in all 99% of the 50,512 Coronavirus isolates curated), then it can be expected that the next 50,512 variations will also contain the conserved sites. Targeting these conserved sites allows the production of a therapeutic that will not become ineffective due to mutation of the virus. In other words, even a "variant form of the virus" will expectedly contain the immutable targeted sites. Targeting those immutable sites avoids the ineffectiveness that is experienced when a therapeutics or vaccine targets a site that has mutated.
Variant have arisen in viruses other that the Coronavirus. Prior government funding in producing anti-HIV monoclonal antibodies have failed due to what the industry calls "virus escape". The anti-HIV monoclonal antibodies VRC01 and VRC02 produced by Vaccine Research Center in conjunction with the NIH were tested for years and then abandoned due to "virus escape". The Company's focus is on producing monoclonal antibodies that target immutable sites to avoid "virus escape".
The Company notes the recent reports of Coronavirus vaccines not being as effective against newly discovered variant of the virus. The Company intends to use its knowledge of the conserved sites on both the Coronavirus and HIV in the production of vaccines that are expected to be less susceptible, or not susceptible at all, to virus mutation.
ENZC is working through the processes necessary to get their product to the next level.
Key words:
Virus Mutation
Virus Escape
Production
What is next?
Coronavirus Treatment Acceleration Program (CTAP) Frequently Asked Questions?
https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap-frequently-asked-questions
It is also a signal to BIG PHARMA/Government that ENZC has the goods to lock down the Coronavirus.
Now the ball is in BIG PHARMA/Government court and the question is "who is gonna pay ball with ENZC?
ENZC possess a must have solution.
This is not a situation of keep the small company down.
This is a situation is how quickly can we get this on the street and "we" is not just ENZC. Now that this information is in the news feeds, people in "high places" will have to step in and get this moving like at warp speed haha.
Seriously though if those in power don't get this moving and there is a bad turn with the coronavirus shame on them. They know the current therapeutics are limited.
The information in the press release says it all:
The Company has always emphasized the need for therapeutics that target conserved and expectedly immutable virus sites - whether the therapeutics is a monoclonal antibody or a preventative vaccine. There is agreement among experts that multiple neutralizing antibodies is critical to effective control of viruses such as the Coronavirus. Recognizing this necessity, if a site is 99% conserved (exits in all 99% of the 50,512 Coronavirus isolates curated), then it can be expected that the next 50,512 variations will also contain the conserved sites. Targeting these conserved sites allows the production of a therapeutic that will not become ineffective due to mutation of the virus. In other words, even a "variant form of the virus" will expectedly contain the immutable targeted sites. Targeting those immutable sites avoids the ineffectiveness that is experienced when a therapeutics or vaccine targets a site that has mutated.
Variant have arisen in viruses other that the Coronavirus. Prior government funding in producing anti-HIV monoclonal antibodies have failed due to what the industry calls "virus escape". The anti-HIV monoclonal antibodies VRC01 and VRC02 produced by Vaccine Research Center in conjunction with the NIH were tested for years and then abandoned due to "virus escape". The Company's focus is on producing monoclonal antibodies that target immutable sites to avoid "virus escape".
So we had PATENT pending NEWS!!!
What is coming down the pike next?
It just keeps getting better and better.
We haven't even reached a critical catalyst that really is going to get this stock rocking.
It is coming in the near to intermediate future.
Agreed,
We are to early in the process for a buy out.
Down the road once some of our product hit the marketplace then the possibility exist.
Even then how do you value something with virtually unlimited solutions for many different diseases.
The Company is also applying Artificial Intelligence [AI] to scan the hundreds of thousands of isolates that exist in 14 other prevalent viruses, ranging from influenza to Rabies to Ebola. Using the Company's proprietary technique for producing fully human monoclonal antibodies directed against these infectious diseases, the Company will produce multiple neutralizing monoclonal antibodies against these viruses. The significance of this approach is well recognized by experts in virology due to the ability of all viruses to mutate and render ineffective initially developed therapeutics.